CURRENT PROJECTS

3RT-085653

Our company holds an exclusive license to a patent for a novel, brain penetrating single-chain antibody to three-repeat tau.  Preclinical studies have shown that this antibody successfully crosses the blood brain barrier, selectively targets and reduces abnormal levels of three-repeat tau and phosphorylated tau without significantly affecting total tau levels, co-localizes with three-repeat tau and targets three-repeat tau to the eadosomal compartment for lysosomal degradation, reduces loss of neuronal cells and astrogliosis, and ameliorates behavioral deficits in both a pre-pulse inhibition paradigm as well as an open field beam break model.

​

We are currently in the process of completing pharmacokinetic and preliminary toxicology studies to advance the development of the antibody towards the eventual goal of an IND application.